Dissection of Level III Axillary Lymph Nodes in Breast Cancer

References

• Jinno H, Inokuchi M, Ito T, et al. The Japanese breast cancer society clinical practice guideline for surgical treatment of breast cancer, 2015 edition. Breast Cancer. 2016;23(3):367–377. doi:10.1007/s12282-016-0671-x26921084
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw. 2017;15(4):433–451. doi:10.6004/jnccn.2017.004428404755
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–575. doi:10.1001/jama.2011.9021304082
   PubMed Web of Science ®Google Scholar
• Liu M, Wang S, Cui S, Duan X, Fan Z, Yu Z. The feasibility of the ACOSOG Z0011 criteria to chinese breast cancer patients: a multicenter study. Sci Rep. 2015;16(5):15241. doi:10.1038/srep15241
   Web of Science ®Google Scholar
• Zhang L, Yu XL, Guo XM. Research progress of axillary management approach for 1–2 sentinel lymph node positive early stage breast cancer patients. Chin J Radiat Oncol. 2016;25(3):292–295.
   Google Scholar
• Straver ME, Rutgers EJ, Russell NS, et al. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer. 2009;45(13):2284–2292. doi:10.1016/j.ejca.2009.04.02919464164
   PubMed Web of Science ®Google Scholar
• Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol. 2002;20(5):1304–1310. doi:10.1200/JCO.2002.20.5.130411870173
   PubMed Web of Science ®Google Scholar
• Alvarado R, Yi M, Le-petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19(10):3177–3184. doi:10.1245/s10434-012-2484-222772869
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–3966. doi:10.1200/JCO.2011.40.836923032615
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-015894097
   PubMed Web of Science ®Google Scholar
• Davies C, Godwin J. Early Breast Cancer Trialists′Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.21802721
   PubMed Web of Science ®Google Scholar
• Dillon MF, Advani V, Masterson C, et al. The value of level III clearance in patients with axillary and sentinel node positive breast cancer. Ann Surg. 2009;249(5):834–839. doi:10.1097/SLA.0b013e3181a4082119387317
   PubMed Web of Science ®Google Scholar
• Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–575. doi:10.1056/NEJMoa02012812192016
   PubMed Web of Science ®Google Scholar
• Rudenstam CM, Zahrieh D, Forbes JF, et al. International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of international breast cancer study group trial 10–93. J Clin Oncol. 2006;24(3):337–344.16344321
   PubMed Web of Science ®Google Scholar
• Martelli G, Boracchi P, De Palo M, et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer. Ann Surg. 2005;242(1):1–6. doi:10.1097/01.sla.0000167759.15670.1415973094
   PubMed Web of Science ®Google Scholar
• Park TS, Thomas SM, Rosenberger LH, et al. The association between extension of axillary surgery and survival in women with N2-3 invasive breast cancer. Ann Surg Oncol. 2018;25(10):3019–3029. doi:10.1245/s10434-018-6587-229978365
   PubMed Web of Science ®Google Scholar
• Kodama H, Nio Y, Iguchi C, Kan N. Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer. Br J Cancer. 2006;95(7):811–816. doi:10.1038/sj.bjc.660336417016485
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Morrow M, von Minckwitz G, Harris JR, Biedenkopf Expert Panel Members. Locoregional treatment of primary breast cancer: consensus recommendations from an international expert panel. Cancer. 2010;116(5):1184–1191. doi:10.1002/cncr.2487420087962
   PubMed Web of Science ®Google Scholar
• Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg. 2004;91(1):38–43. doi:10.1002/bjs.437214716791
   PubMed Web of Science ®Google Scholar
• Kong Y, Yang A, Xie X. Impact of the extent of axillary surgery in patients with N2–3 disease in the de-escalation era: a propensity score-matched study. Clin Transl Oncol. 2020. doi:10.1007/s12094-020-02444-1
   Web of Science ®Google Scholar
• Yildirim E, Berberoglu U. Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg. 2007;31(2):276–289. doi:10.1007/s00268-006-0487-517219275
   PubMed Web of Science ®Google Scholar
• Barros AC, Andrade FE, Bevilacqua JL, et al. Radicality effect of adding an interpectoral to a subpectoral approach for dissection of level III axillary lymph nodes in breast cancer. Tumori. 2013;99(4):500–504. doi:10.1177/03008916130990041024471202
   PubMed Web of Science ®Google Scholar
• Rosen PP, Lesser ML, Kinne DW, Beattie EJ. Discontinuous or “skip” metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg. 1983;197(3):276–283. doi:10.1097/00000658-198303000-000066830335
   PubMed Web of Science ®Google Scholar
• Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion: an analysis of 539 cases. Cancer. 1987;59(4):682–687. doi:10.1002/1097-0142(19870215)59:4<682::AID-CNCR2820590403>3.0.CO;2-Z3802027
   PubMed Web of Science ®Google Scholar
• Khafagy M, Mostafa A, Fakhr I. Distribution of axillary lymph node metastases in different levels and groups in breast cancer, a pathological study. J Egypt Natl Canc Inst. 2011;23(1):25–30. doi:10.1016/j.jnci.2011.07.00422099933
   PubMedGoogle Scholar
• Yangtao O, Jinfeng L, Tianfeng W, Lin BY. Exploration of the extent of axillary dissection for patients with node positive primary breast cancer. Chin J Surg. 2005;43(3):298–300.15842936
   PubMedGoogle Scholar
• Fan Z, Li J, Wang T, et al. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy. Breast. 2013;22(6):1161–1165. doi:10.1016/j.breast.2013.08.00424080493
   PubMed Web of Science ®Google Scholar
• Toma S, Leonessa F, Romanini A, et al. Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer. Anticancer Res. 1991;11(4):1439–1443.1746901
   PubMed Web of Science ®Google Scholar
• Ung O, Tan M, Chua B, Barraclough B. Complete axillary dissection: a technique that still has relevance in contemporary management of breast cancer. ANZ J Surg. 2006;76(6):518–521. doi:10.1111/j.1445-2197.2006.03765.x16768781
   PubMed Web of Science ®Google Scholar
• Wang R, Chen J, Tian CX, et al. High risk factors of the third level of lymphatic metastasis in breast cancer patients received radical modified mastectomy: an analysis of 747 cases. Chin J Surg. 2014;52(5):346–349.25034741
   PubMedGoogle Scholar
• Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg. 2001;25(6):767–772. doi:10.1007/s00268-001-0003-x11376414
   PubMed Web of Science ®Google Scholar
• Lucci A, McCall LM, Beitsch PD, et al., American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with slnd alone in the American college of surgeons oncology group trial z0011. J Clin Oncol. 2007;25(24):3657–3663. doi:10.1200/JCO.2006.07.406217485711
   PubMed Web of Science ®Google Scholar
• Somers RG, Jablon LK, Kaplan MJ, Sandler GL, Rosenblatt NK. The use of closed suction drainage after lumpectomy and axillary node dissection for breast cancer. A prospective randomized trial. Ann Surg. 1992;215(2):146–149. doi:10.1097/00000658-199202000-000091546900
   PubMed Web of Science ®Google Scholar
• Muscolino G, Leo E, Sacchini V, Bedini AV, Luini A. Resectable breast cancer: axillary dissection sparing pectoralis muscles and nerves. Eur J Surg Oncol. 1998;14:429–433.
   Google Scholar
• Pai A, Gupta P, Raina S, Nadkarni MS, Parmar V, Badwe RA. Interpectoral approach to dissection of the axillary apex: an elegant and effective approach. J Surg Oncol. 2006;94(3):252–254.16900515
   PubMed Web of Science ®Google Scholar
• Hadjiminas DJ, Zacharioudakis KE. Direct transpectoral approach for level III axillary lymph node clearance. Ann R Coll Surg Engl. 2014;96(6):481–482. doi:10.1308/rcsann.2014.96.6.48125198984
   PubMed Web of Science ®Google Scholar